3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Prostatic Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
4
Carcinoma, Non-Small-Cell Lung
4
Esophageal Neoplasms
3
Stomach Neoplasms
2
Oropharyngeal Neoplasms
2
Multiple Myeloma
2
Mouth Neoplasms
2
Lymphoma, Large B-Cell, Diffuse
2
Leukemia, Myeloid, Acute
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Breast Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Tongue Neoplasms
1
Retinoblastoma
1
Recurrence
1
Rectal Neoplasms
1
Precancerous Conditions
1
Pancreatic Neoplasms
1
Osteoporosis
1
Obesity
1
Neoplasms
1
Neoplasm Metastasis
1
Meningioma
1
Melanoma
1
Lymphoma, Mantle-Cell
1
Interventions
Gemcitabine
26
Capecitabine
16
Oxaliplatin
14
Fluorouracil
13
Cisplatin
12
Leucovorin
9
pembrolizumab
5
Erlotinib Hydrochloride
5
Bevacizumab
5
durvalumab
4
Trastuzumab
4
Specimen Handling
4
Sorafenib
4
Magnetic Resonance Spectroscopy
4
130-nm albumin-bound paclitaxel
4
trifluridine tipiracil drug combination
3
Lapatinib
3
Irinotecan
3
Carboplatin
3
Biopsy
3
tremelimumab
2
toripalimab
2
regorafenib
2
lenvatinib
2
dehydroftorafur
2
cobimetinib
2
atezolizumab
2
anlotinib
2
Nivolumab
2
N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Gallbladder Neoplasms
×
Observation
×
Clear all
NCT04333927
2020-06-23
ACCORD
Sun Yat-sen University
Phase 2
Unknown
92 enrolled